Cefmenoxime hydrochloride is a third-generation cephalosporin antibiotic.

Cefetamet pivoxil hydrochloride is an oral third generation cephalosporin antibiotic.

Cefdinir (Omnicef)

CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively.

CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP).

CDP-840 (CDP840.

CDP-840 (CDP840.

CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.

CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2.

Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays..

Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM.

CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA)..

CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively)..

CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA.

CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM.

CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM.

CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM.

CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM.

CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively.

CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.

CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM.

CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM..

CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485.

CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways.

CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4.

CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF.

CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay.

CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor.

CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth.